Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ROGER KERESZTES

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1770638868
CMS profile
306943
Location
STONY BROOK, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$44.45

2 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $44.45 2

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
AstraZeneca Pharmaceuticals LP $44.45 2

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ROGER KERESZTES

NPI 1770638868 · CMS profile ID 306943

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

STONY BROOK, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1770638868?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ROGER KERESZTES, NPI 1770638868, CMS profile ID 306943. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1770638868?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). ROGER KERESZTES, NPI 1770638868, CMS profile ID 306943. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1770638868?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
ROGER KERESZTES, NPI 1770638868, CMS profile ID 306943, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1770638868?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

2 matching records · $44.45 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 2 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–2 of 2.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AstraZeneca Pharmaceuticals LP $22.3805/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025062487 CMS
AstraZeneca Pharmaceuticals LP $22.0701/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025050461 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2023 $44.45 2
PY2024 $55.34 2
PY2025 $14.92 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $27,621.65 4
PY2024 Principal investigator $138,690.67 8
PY2023 Principal investigator $81,484.34 14
PY2022 Principal investigator $95,857.37 13
PY2021 Principal investigator $260,611.75 11
PY2020 Principal investigator $254,132.68 45
PY2019 Principal investigator $306,187.59 54

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

54 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme Corporation $47.49 12/19/2019 Non-covered Recipient Entity
STONY BROOK UNIVERSITY MEDICAL CENTER CANCER CENTER
A Phase III, Randomized, Double-Blind Trial of Platinum Doublet Chemotherapy ,-Pembrolizumab MK-3475 as Neoadjuvant,Adjuvant Therapy for Participants with Resectable Stage IIB or IIIA Non-Small Cell Lung Cancer NSCLC KEYNOTE-671 No dispute reported 06/30/2026 691501783
Principal investigator 1 AbbVie, Inc. $4,796.00 12/17/2019 Non-covered Recipient Entity
University Of The State Of New York University At Buffalo
M16-298 No dispute reported 06/30/2026 647576751
Principal investigator 1 AbbVie, Inc. $7,220.00 12/12/2019 Non-covered Recipient Entity
University Of The State Of New York University At Buffalo
M16-298 No dispute reported 06/30/2026 647576747
Principal investigator 1 AbbVie, Inc. $2,765.00 12/12/2019 Non-covered Recipient Entity
University Of The State Of New York University At Buffalo
M16-298 No dispute reported 06/30/2026 647576749
Principal investigator 1 AbbVie, Inc. $9,428.00 12/06/2019 Non-covered Recipient Entity
University Of The State Of New York University At Buffalo
M16-298 No dispute reported 06/30/2026 647576753
Principal investigator 1 Merck Sharp & Dohme Corporation $16,239.36 11/29/2019 Non-covered Recipient Entity
STONY BROOK UNIVERSITY MEDICAL CENTER CANCER CENTER
A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy ,- Pembrolizumab MK-3475 as Neoadjuvant,Adjuvant Therapy for Participants with Resectable Stage II, IIIA, and Resectable IIIB T3-4N2 Non-small Cell Lung Cancer NSCLC KEYNOTE-671 No dispute reported 06/30/2026 691537505
Principal investigator 1 Genentech, Inc. $500.00 11/19/2019 Non-covered Recipient Entity
ADVARRA INC
BF1RST No dispute reported 06/30/2026 857128685
Principal investigator 1 AbbVie, Inc. $187.85 11/14/2019 Non-covered Recipient Entity
University Of The State Of New York University At Buffalo
M14-360 No dispute reported 06/30/2026 647576755
Principal investigator 1 Merck Sharp & Dohme Corporation $632.00 11/08/2019 Non-covered Recipient Entity
STONY BROOK UNIVERSITY MEDICAL CENTER CANCER CENTER
A Phase III, Randomized, Double-Blind Trial of Platinum Doublet Chemotherapy ,-Pembrolizumab MK-3475 as Neoadjuvant,Adjuvant Therapy for Participants with Resectable Stage IIB or IIIA Non-Small Cell Lung Cancer NSCLC KEYNOTE-671 No dispute reported 06/30/2026 691540565
Principal investigator 1 Merck Sharp & Dohme Corporation $2,743.75 10/30/2019 Non-covered Recipient Entity
RESEARCH FOUNDATION STATE UNIVERSITY OF NEW YORK
A Phase III, Randomized, Double-Blind Trial of Platinum Doublet Chemotherapy ,-Pembrolizumab MK-3475 as Neoadjuvant,Adjuvant Therapy for Participants with Resectable Stage IIB or IIIA Non-Small Cell Lung Cancer NSCLC KEYNOTE-671 No dispute reported 06/30/2026 691486075
Principal investigator 1 Genentech, Inc. $1,450.00 10/29/2019 Non-covered Recipient Entity
ADVARRA INC
BF1RST No dispute reported 06/30/2026 857128681
Principal investigator 1 Merck Sharp & Dohme Corporation $55,282.00 10/25/2019 Non-covered Recipient Entity
RESEARCH FOUNDATION STATE UNIVERSITY OF NEW YORK
A Phase III, Randomized, Double-Blind Trial of Platinum Doublet Chemotherapy ,-Pembrolizumab MK-3475 as Neoadjuvant,Adjuvant Therapy for Participants with Resectable Stage IIB or IIIA Non-Small Cell Lung Cancer NSCLC KEYNOTE-671 No dispute reported 06/30/2026 691486079
Principal investigator 1 Novocure Inc. $325.00 09/24/2019 Non-covered Recipient Entity
Advarra Inc
EF-24 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields) concurrent with standard of care therapies for treatment of stage 4 non-small cell lung cancer (NSCLC) following platinum failure. No dispute reported 06/30/2026 694526015
Principal investigator 1 Novocure Inc. $525.00 09/24/2019 Non-covered Recipient Entity
Advarra Inc
EF-24 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields) concurrent with standard of care therapies for treatment of stage 4 non-small cell lung cancer (NSCLC) following platinum failure. No dispute reported 06/30/2026 694526017
Principal investigator 1 Genentech, Inc. $4,063.00 09/23/2019 Non-covered Recipient Entity
THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
BF1RST No dispute reported 06/30/2026 857131947
Principal investigator 1 AbbVie, Inc. $7,299.00 09/16/2019 Non-covered Recipient Entity
University Of The State Of New York University At Buffalo
M16-298 No dispute reported 06/30/2026 647576739
Principal investigator 1 AbbVie, Inc. $5,296.00 09/16/2019 Non-covered Recipient Entity
University Of The State Of New York University At Buffalo
M16-298 No dispute reported 06/30/2026 647576741
Principal investigator 1 AbbVie, Inc. $250.00 09/16/2019 Non-covered Recipient Entity
University Of The State Of New York University At Buffalo
M16-298 No dispute reported 06/30/2026 647576743
Principal investigator 1 AbbVie, Inc. $1,180.00 09/11/2019 Non-covered Recipient Entity
University Of The State Of New York University At Buffalo
M16-298 No dispute reported 06/30/2026 647576745
Principal investigator 1 AbbVie, Inc. $2,843.75 08/30/2019 Non-covered Recipient Entity
University Of The State Of New York University At Buffalo
M16-298 No dispute reported 06/30/2026 647576733
Principal investigator 1 Merck Sharp & Dohme Corporation $481.39 08/27/2019 Non-covered Recipient Entity
STONY BROOK UNIVERSITY MEDICAL CENTER CANCER CENTER
A Phase III, Randomized, Double-Blind Trial of Platinum Doublet Chemotherapy ,-Pembrolizumab MK-3475 as Neoadjuvant,Adjuvant Therapy for Participants with Resectable Stage IIB or IIIA Non-Small Cell Lung Cancer NSCLC KEYNOTE-671 No dispute reported 06/30/2026 691395943
Principal investigator 1 AbbVie, Inc. $2,564.00 08/21/2019 Non-covered Recipient Entity
University Of The State Of New York University At Buffalo
M14-360 No dispute reported 06/30/2026 647576735
Principal investigator 1 AbbVie, Inc. $812.50 08/19/2019 Non-covered Recipient Entity
University Of The State Of New York University At Buffalo
M14-360 No dispute reported 06/30/2026 647576737
Principal investigator 1 Eli Lilly and Company $13,279.50 08/06/2019 Non-covered Recipient Entity
RESEARCH FOUNDATION OF STATE UNIV OF NY
A RANDOMIZED PHASE 2 TRIAL OF AM0010 IN COMBINATION WITH PEMBROLIZUMAB VS. PEMBROLIZUMAB ALONE AS FIRST-LINE THERAPY IN PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER WHOSE TUMORS HAVE HIGH PD-L1 EXPRESSION No dispute reported 06/30/2026 654292481
Principal investigator 1 Novocure Inc. $750.00 08/06/2019 Non-covered Recipient Entity
The Research Foundation for the State University of New York
EF-24 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields) in Combination with PD-1 Inhibitors or Docetaxel, for Second Line Treatment of Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 694526035
Principal investigator 1 Genentech, Inc. $23,355.00 08/05/2019 Non-covered Recipient Entity
THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
BF1RST No dispute reported 06/30/2026 857131943
Principal investigator 1 Eli Lilly and Company $13.55 07/25/2019 Non-covered Recipient Entity
SHARP MESA VISTA HOSPITAL
A RANDOMIZED PHASE 2 TRIAL OF AM0010 IN COMBINATION WITH PEMBROLIZUMAB VS. PEMBROLIZUMAB ALONE AS FIRST-LINE THERAPY IN PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER WHOSE TUMORS HAVE HIGH PD-L1 EXPRESSION No dispute reported 06/30/2026 654290461
Principal investigator 1 AstraZeneca Pharmaceuticals LP $14,493.10 07/23/2019 Non-covered Recipient Entity
The Research Foundation Of State University Of New York
A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with Stage I-III Limited Disease Small-Cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy (ADRIATIC) No dispute reported 06/30/2026 684993225
Principal investigator 1 Incyte Corporation $295.00 07/05/2019 Non-covered Recipient Entity
SUNY UPSTATE SYRACUSE
An Open Label Phase 12 Study of INCB039110 in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic Non Small Cell Lung Cancer No dispute reported 06/30/2026 666457527
Principal investigator 1 Novocure Inc. $406.25 07/03/2019 Non-covered Recipient Entity
The Research Foundation for the State University of New York
EF-24 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields) in Combination with PD-1 Inhibitors or Docetaxel, for Second Line Treatment of Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 694526033
Principal investigator 1 AbbVie, Inc. $5,415.00 06/06/2019 Non-covered Recipient Entity
University Of The State Of New York University At Buffalo
M16-298 No dispute reported 06/30/2026 647576731
Principal investigator 1 Helsinn Healthcare SA $11,000.00 06/05/2019 Non-covered Recipient Entity
THE RESEARCH FOUNDATION FOR SUNY
A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer NSCLC No dispute reported 06/30/2026 675777625
Principal investigator 1 AbbVie, Inc. $750.00 05/20/2019 Non-covered Recipient Entity
University Of The State Of New York University At Buffalo
M16-298 No dispute reported 06/30/2026 647576725
Principal investigator 1 Novocure Inc. $3,150.00 05/03/2019 Non-covered Recipient Entity
The Research Foundation for the State University of New York
EF-24 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields) in Combination with PD-1 Inhibitors or Docetaxel, for Second Line Treatment of Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 694526031
Principal investigator 1 AbbVie, Inc. $660.00 05/02/2019 Non-covered Recipient Entity
University Of The State Of New York University At Buffalo
M16-298 No dispute reported 06/30/2026 647576727
Principal investigator 1 AbbVie, Inc. $1,000.00 05/01/2019 Non-covered Recipient Entity
University Of The State Of New York University At Buffalo
M16-298 No dispute reported 06/30/2026 647576729
Principal investigator 1 AbbVie, Inc. $1,453.75 04/29/2019 Non-covered Recipient Entity
University Of The State Of New York University At Buffalo
M16-298 No dispute reported 06/30/2026 647576723
Principal investigator 1 Merck Sharp & Dohme Corporation $11.97 04/25/2019 Non-covered Recipient Entity
STONY BROOK UNIVERSITY MEDICAL CENTER CANCER CENTER
A Phase III, Randomized, Double-Blind Trial of Platinum Doublet Chemotherapy ,-Pembrolizumab MK-3475 as Neoadjuvant,Adjuvant Therapy for Participants with Resectable Stage IIB or IIIA Non-Small Cell Lung Cancer NSCLC KEYNOTE-671 No dispute reported 06/30/2026 691352269
Principal investigator 1 AbbVie, Inc. $1,830.00 04/22/2019 Non-covered Recipient Entity
University Of The State Of New York University At Buffalo
M16-298 No dispute reported 06/30/2026 647576721
Principal investigator 1 Genentech, Inc. $34,970.62 04/22/2019 Non-covered Recipient Entity
THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
BF1RST No dispute reported 06/30/2026 857131937
Principal investigator 1 Novocure Inc. $3,112.50 04/18/2019 Non-covered Recipient Entity
The Research Foundation for the State University of New York
EF-24 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields) in Combination with PD-1 Inhibitors or Docetaxel, for Second Line Treatment of Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 694526029
Principal investigator 1 Genentech, Inc. $295.00 04/09/2019 Non-covered Recipient Entity
ADVARRA INC
BF1RST No dispute reported 06/30/2026 857128675
Principal investigator 1 Merck Sharp & Dohme Corporation $65.61 03/26/2019 Non-covered Recipient Entity
STONY BROOK UNIVERSITY MEDICAL CENTER CANCER CENTER
A Phase III, Randomized, Double-Blind Trial of Platinum Doublet Chemotherapy ,-Pembrolizumab MK-3475 as Neoadjuvant,Adjuvant Therapy for Participants with Resectable Stage IIB or IIIA Non-Small Cell Lung Cancer NSCLC KEYNOTE-671 No dispute reported 06/30/2026 691359455
Principal investigator 1 Novocure Inc. $525.00 03/14/2019 Non-covered Recipient Entity
The Research Foundation for the State University of New York
EF-24 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields) in Combination with PD-1 Inhibitors or Docetaxel, for Second Line Treatment of Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 694526027
Principal investigator 1 PFIZER INC. $5,452.50 03/01/2019 Non-covered Recipient Entity
The Research Foundation for The State University of New York
A MULTICENTER OPENLABEL PHASE 1B2 STUDY TO EVALUATE SAFETY AND EFFICACY OF AVELUMAB MSB0010718C IN COMBINATION WITH CHEMOTHERAPY WITH OR WITHOUT OTHER ANTICANCER IMMUNOTHERAPIES AS FIRSTLINE TREATMENT IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 671619145
Principal investigator 1 AbbVie, Inc. $1,546.87 02/28/2019 Non-covered Recipient Entity
University Of The State Of New York University At Buffalo
M16-298 No dispute reported 06/30/2026 647576715
Principal investigator 1 Genentech, Inc. $115.00 02/20/2019 Non-covered Recipient Entity
ADVARRA INC
BF1RST No dispute reported 06/30/2026 857128671
Principal investigator 1 Merck Sharp & Dohme Corporation $937.50 01/30/2019 Non-covered Recipient Entity
STONY BROOK UNIVERSITY MEDICAL CENTER CANCER CENTER
A Phase III, Randomized, Double-Blind Trial of Platinum Doublet Chemotherapy ,-Pembrolizumab MK-3475 as Neoadjuvant,Adjuvant Therapy for Participants with Resectable Stage IIB or IIIA Non-Small Cell Lung Cancer NSCLC KEYNOTE-671 No dispute reported 06/30/2026 691309613
Principal investigator 1 Merck Sharp & Dohme Corporation $5,425.00 01/30/2019 Non-covered Recipient Entity
STONY BROOK UNIVERSITY MEDICAL CENTER CANCER CENTER
A Phase III, Randomized, Double-Blind Trial of Platinum Doublet Chemotherapy ,-Pembrolizumab MK-3475 as Neoadjuvant,Adjuvant Therapy for Participants with Resectable Stage IIB or IIIA Non-Small Cell Lung Cancer NSCLC KEYNOTE-671 No dispute reported 06/30/2026 691310899
Principal investigator 1 Merck Sharp & Dohme Corporation $2,150.00 01/30/2019 Non-covered Recipient Entity
STONY BROOK UNIVERSITY MEDICAL CENTER CANCER CENTER
A Phase III, Randomized, Double-Blind Trial of Platinum Doublet Chemotherapy ,-Pembrolizumab MK-3475 as Neoadjuvant,Adjuvant Therapy for Participants with Resectable Stage IIB or IIIA Non-Small Cell Lung Cancer NSCLC KEYNOTE-671 No dispute reported 06/30/2026 691311069
Principal investigator 1 AbbVie, Inc. $3,853.12 01/29/2019 Non-covered Recipient Entity
University Of The State Of New York University At Buffalo
M16-298 No dispute reported 06/30/2026 647576717
Principal investigator 1 Genentech, Inc. $31,888.12 01/14/2019 Non-covered Recipient Entity
THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
BF1RST No dispute reported 06/30/2026 857131933
Principal investigator 1 Genentech, Inc. $1,450.00 01/08/2019 Non-covered Recipient Entity
ADVARRA INC
BF1RST No dispute reported 06/30/2026 857128667
Principal investigator 1 AbbVie, Inc. $9,606.54 01/02/2019 Non-covered Recipient Entity
University Of The State Of New York University At Buffalo
M16-298 No dispute reported 06/30/2026 647576719